The «cost-benefit» analysis of new antiepileptic drugs

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 111, Issue 10, 2011, Pages 39-43

  Vlasov, P N ^a   Orekhova, N V ^a  

^a NONE

Author keywords

Epilepsy; Lamotrigine; Levetiracetam; Oxcarbazepine; Pharmacoeconomics; Topiramate; cost benefits

Indexed keywords

ANTICONVULSIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; EPILEPSY; FEE; FEMALE; HUMAN; MALE;

ADOLESCENT; ADULT; ANTICONVULSANTS; COST-BENEFIT ANALYSIS; EPILEPSY; FEES, PHARMACEUTICAL; FEMALE; HUMANS; MALE; YOUNG ADULT;

EID: 84860247615     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Blais L., Sheehy O., St-Hilaire J.M. et al. Research Centre, University of Montreal Hospital, Montreal, Quebec, Canada. Source Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy. Pharmacoeconomics 2005; 23: 5: 493-503.
2. Guk-Hee Suh, Sang Keol Lee. Economic Evaluation of Add-on Levetiracetam for the Treatment of Refractory Partial Epilepsy in Korea. Psychiatry Investigation 2009; 6: 3: 185-193.
3. Jacques Le Lorier, Philippe Godfroid, Yvonne Hart, Richard Roberts. Levetiracetam: an innovative and cost-effective add-on drug for refractory partial epilepsy. Expert Review of Pharmacoeconomics & Outcomes Research 2004; 4: 2: 143-151.
4. Messori A., Trippoli S., Becagli P. et al. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. Eur J Clin Pharmacol 1998; 53: 6: 421-427.